213
Views
4
CrossRef citations to date
0
Altmetric
Case Reports

Preoperative treatment of benign insulinoma: diazoxide or somatostatin analogues?

, ORCID Icon, &
Pages 136-139 | Received 05 Apr 2020, Accepted 25 Apr 2020, Published online: 18 May 2020

References

  • Service FJ, Mc Mahon MM, O’Brien PC, et al. Functioning insulinoma – incidence, recurrence and long-term survival of patients: a 60-year study. Mayo Clin Proc. 1991;66(7):711–719.
  • Iglesias P, Díez JJ. Management of endocrine disease: a clinical update on tumor-induced hypoglycemia. Eur J Endocrinol. 2014;170(4):R147–R157.
  • Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg. 1986;10(4):586–592.
  • Maggio I, Mollica V, Brighi N, et al. The functioning side of the pancreas: a review on insulinomas. J Endocrinol Invest. 2020;43(2):139–148.
  • Gill GV, Rauf O, MacFarlane IA. Diazoxide treatment for insulinoma: a national UK survey. Postgrad Med J. 1997; 73(864):640–641.
  • Komatsu Y, Nakamura A, Takihata M, et al. Safety and tolerability of diazoxide in Japanese patients with hyperinsulinemic hypoglycemia. Endocr J. 2016; 63(3):311–314.
  • Niitsu Y, Minami I, Izumiyama H, et al. Clinical outcomes of 20 Japanese patients with insulinoma treated with diazoxide. Endocr J. 2019; 66(2):149–155.
  • Ito T, Igarashi H, Jensen RT. Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances. Best Pract Res Clin Gastroenterol. 2012;26(6):737–753.
  • Vezzosi D, Bennet A, Courbon F, et al. Short- and long-term somatostatin analogue treatment in patients with hypoglycaemia related to endogenous hyperinsulinism. Clin Endocrinol (Oxf)). 2008;68(6):904–911.
  • Matej A, Bujwid H, Wroński J. Glycemic control in patients with insulinoma. Hormones (Athens)). 2016;15(4):489–499.
  • Gama R, Marks V, Wright J, et al. Octreotide exacerbated fasting hypoglycaemia in a patient with a proinsulinoma; the glucostatic importance of pancreatic glucagon. Clin Endocrinol (Oxf)). 1995; 43(1):117–120. discussion 120–2.
  • Dimitriadis GK, Weickert MO, Randeva HS, et al. Medical management of secretory syndromes related to gastroenteropancreatic neuroendocrine tumours. Endocr Rel Cancer. 2016;23(9):R423–R436.
  • Brown E, Watkin D, Evans J, et al. Multidisciplinary management of refractory insulinomas. Clin Endocrinol. 2018;88(5):615–624.
  • Tirosh A, Stemmer SM, Solomonov E, et al. Pasireotide for malignant insulinoma. Hormones (Athens)). 2016;15(2):271–276.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.